biostudies-literatureKwon JHNIAID NIH HHSNHLBI NIH HHSNIH HHS697-718https://www.ebi.ac.uk/biostudies/studies/S-EPMC8419637biostudies-literatureUnknown13(5)Our prior work and the work of others have demonstrated that asthma increases the risk of a broad range of both respiratory (<i>e.g.</i>, pneumonia and pertussis) and non-respiratory (<i>e.g.</i>, zoster and appendicitis) infectious diseases as well as inflammatory diseases (<i>e.g.</i>, celiac disease and myocardial infarction [MI]), suggesting the systemic disease nature of asthma and its impact beyond the airways. We call these conditions asthma-associated infectious and inflammatory multimorbidities (AIMs). At present, little is known about why some people with asthma are at high-risk of AIMs, and others are not, to the extent to which controlling asthma reduces the risk of AIMs and which specific therapies mitigate the risk of AIMs. These questions represent a significant knowledge gaAllergy, asthma & immunology researchRisk, Mechanisms and Implications of Asthma-Associated Infectious and Inflammatory Multimorbidities (AIMs) among Individuals With Asthma: a Systematic Review and a Case Study.PMC8419637R21 AI142702R01 HL 126667R01 HL126667R21 AI 142702Liu HJuhn YJKwon JHKing KPark MSohn SWi CISeol HYRyu EfalseRisk, Mechanisms and Implications of Asthma-Associated Infectious and Inflammatory Multimorbidities (AIMs) among Individuals With Asthma: a Systematic Review and a Case Study.Our prior work and the work of others have demonstrated that asthma increases the risk of a broad range of both respiratory (<i>e.g.</i>, pneumonia and pertussis) and non-respiratory (<i>e.g.</i>, zoster and appendicitis) infectious diseases as well as inflammatory diseases (<i>e.g.</i>, celiac disease and myocardial infarction [MI]), suggesting the systemic disease nature of asthma and its impact beyond the airways. We call these conditions asthma-associated infectious and inflammatory multimorbidities (AIMs). At present, little is known about why some people with asthma are at high-risk of AIMs, and others are not, to the extent to which controlling asthma reduces the risk of AIMs and which specific therapies mitigate the risk of AIMs. These questions represent a significant knowledge ga2021-01-01T00:00:00Z2021 Sep2025-04-22T06:06:57.156Z2022-02-11T10:53:28.953ZS-EPMC84196373448625610.4168/aair.2021.13.5.697